23ME 01473
Alternative Names: '1473; 23ME-001473; 23ME-01473; 23ME-1473Latest Information Update: 15 Jun 2024
At a glance
- Originator 23andMe
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Pharmacodynamics data from a phase I trial in Solid tumours released by 23andMe
- 07 Mar 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion) (NCT06290388)